Similarly, the combination of TIL with BRAF inhibitors (inducing cell apoptosis and the release of antigens which initiate T-cell activation) or BRAF/MEK inhibitors could be of interest in the treatment of metastatic melanoma. Here, BRAF is linked to metastatic melanoma.